Exact Imaging Secures $10M to Propel Prostate Cancer Detection
February 21, 2026, 3:53 pm
Exact Imaging, a pioneer in urologic imaging, announced a significant $10 million financing round. This capital infusion accelerates the global sales and adoption of its flagship ExactVu™ micro-ultrasound system. ExactVu™ offers high-resolution prostate cancer detection, representing a major advancement in precision medicine. Landmark clinical validation, including the OPTIMUM study published in JAMA, confirmed its efficacy. This study demonstrated ExactVu™ to be non-inferior to MRI-fusion biopsy for prostate cancer detection in biopsy-naïve men. These findings earned recognition at the European Association of Urology Congress.
The company achieved substantial commercial expansion throughout 2025. It launched a dedicated North American salesforce. It also secured critical distribution partnerships across Europe, Japan, South Korea, Taiwan, Brazil, Mexico, and other key international markets. With a robust portfolio of over 100 patents and serving more than 300 customers worldwide, Exact Imaging is strategically positioned for aggressive market growth. The new funds will amplify its commercial footprint globally. This ensures advanced prostate cancer diagnosis reaches more patients. iGan Partners led the financing round, underscoring their long-standing strategic support and commitment to medical technology innovation. This investment solidifies Exact Imaging’s pivotal role in transforming early cancer detection and urologic care.
Exact Imaging secured $10 million in its latest financing round. This significant investment fuels the company's ambitious global expansion plans. The funds will accelerate sales and adoption of its ExactVu™ micro-ultrasound system. This technology represents a critical advancement in prostate cancer detection.
ExactVu™ provides high-resolution micro-ultrasound imaging. It offers unprecedented clarity for urologic procedures. This precision enables earlier and more accurate prostate cancer detection. The system is built on a strong intellectual property foundation. It boasts a portfolio of over 100 patents. More than 300 customers worldwide already utilize ExactVu™.
Clinical validation underpins the system's efficacy. Exact Imaging published its landmark OPTIMUM study in JAMA. This prestigious journal selected the study as Editor’s Choice. The OPTIMUM study delivered compelling results. It showed ExactVu™ micro-ultrasound is non-inferior to MRI-fusion biopsy. This applies to prostate cancer detection in biopsy-naïve men. These findings garnered significant attention. They were featured in the "Game Changer" session. This occurred at the European Association of Urology (EAU) Congress in Madrid. Such clinical evidence strengthens ExactVu™’s position as a vital diagnostic tool. It provides confidence to urologists and patients alike.
Commercial momentum accelerated throughout 2025. Exact Imaging achieved significant progress on multiple fronts. The company reported record system sales. It is strategically positioned to double sales in 2026. This growth is driven by expanding market reach. A dedicated North American salesforce launched. This boosted domestic penetration. International distribution agreements also expanded the company's footprint. New partners now serve Europe, Japan, South Korea, Taiwan, Brazil, and Mexico. These partnerships are crucial for wider global adoption. They bring ExactVu™ to diverse healthcare systems.
The $10 million financing round provides essential capital. It allows Exact Imaging to scale its commercial operations worldwide. Randy AuCoin, Exact Imaging’s Chief Executive Officer, leads this charge. The company aims to bring ExactVu™ to many more urologists and patients. This capital injection is a major milestone. It ensures the company can meet growing global demand. It supports expanded production and commercial infrastructure.
iGan Partners led the investment round. iGan Partners is a healthcare-focused investment firm. They specialize in medtech and healthcare technology companies. iGan Partners has been a long-term strategic supporter of Exact Imaging. They are the largest shareholder. Sam Ifergan, founder of iGan Partners, co-founded Exact Imaging. This deep relationship ensures continuous support. iGan has assisted with company formation. They also facilitated intellectual property licensing. Their support spans clinical development and initial commercialization. All financing rounds to date have seen their backing. This partnership provides critical sector expertise and operational guidance. It helps scale innovations that improve patient outcomes.
The impact of ExactVu™ on prostate cancer care is profound. It offers a more precise, accessible alternative for diagnosis. Early detection remains key to successful treatment. The system’s high resolution aids in targeting suspicious lesions. This minimizes unnecessary biopsies. It also reduces patient discomfort. Exact Imaging’s technology addresses a critical need in men’s health. It provides urologists with a powerful diagnostic solution.
Exact Imaging is set for continued strong growth. The company’s innovative technology, combined with robust clinical evidence, sets it apart. Its expanding global commercial footprint promises broad market penetration. This financing round reinforces its leadership in micro-ultrasound imaging. Exact Imaging is transforming prostate cancer diagnosis. It is improving patient outcomes worldwide. The future of urologic imaging looks sharper, thanks to ExactVu™.
The company achieved substantial commercial expansion throughout 2025. It launched a dedicated North American salesforce. It also secured critical distribution partnerships across Europe, Japan, South Korea, Taiwan, Brazil, Mexico, and other key international markets. With a robust portfolio of over 100 patents and serving more than 300 customers worldwide, Exact Imaging is strategically positioned for aggressive market growth. The new funds will amplify its commercial footprint globally. This ensures advanced prostate cancer diagnosis reaches more patients. iGan Partners led the financing round, underscoring their long-standing strategic support and commitment to medical technology innovation. This investment solidifies Exact Imaging’s pivotal role in transforming early cancer detection and urologic care.
Exact Imaging secured $10 million in its latest financing round. This significant investment fuels the company's ambitious global expansion plans. The funds will accelerate sales and adoption of its ExactVu™ micro-ultrasound system. This technology represents a critical advancement in prostate cancer detection.
ExactVu™ provides high-resolution micro-ultrasound imaging. It offers unprecedented clarity for urologic procedures. This precision enables earlier and more accurate prostate cancer detection. The system is built on a strong intellectual property foundation. It boasts a portfolio of over 100 patents. More than 300 customers worldwide already utilize ExactVu™.
Clinical validation underpins the system's efficacy. Exact Imaging published its landmark OPTIMUM study in JAMA. This prestigious journal selected the study as Editor’s Choice. The OPTIMUM study delivered compelling results. It showed ExactVu™ micro-ultrasound is non-inferior to MRI-fusion biopsy. This applies to prostate cancer detection in biopsy-naïve men. These findings garnered significant attention. They were featured in the "Game Changer" session. This occurred at the European Association of Urology (EAU) Congress in Madrid. Such clinical evidence strengthens ExactVu™’s position as a vital diagnostic tool. It provides confidence to urologists and patients alike.
Commercial momentum accelerated throughout 2025. Exact Imaging achieved significant progress on multiple fronts. The company reported record system sales. It is strategically positioned to double sales in 2026. This growth is driven by expanding market reach. A dedicated North American salesforce launched. This boosted domestic penetration. International distribution agreements also expanded the company's footprint. New partners now serve Europe, Japan, South Korea, Taiwan, Brazil, and Mexico. These partnerships are crucial for wider global adoption. They bring ExactVu™ to diverse healthcare systems.
The $10 million financing round provides essential capital. It allows Exact Imaging to scale its commercial operations worldwide. Randy AuCoin, Exact Imaging’s Chief Executive Officer, leads this charge. The company aims to bring ExactVu™ to many more urologists and patients. This capital injection is a major milestone. It ensures the company can meet growing global demand. It supports expanded production and commercial infrastructure.
iGan Partners led the investment round. iGan Partners is a healthcare-focused investment firm. They specialize in medtech and healthcare technology companies. iGan Partners has been a long-term strategic supporter of Exact Imaging. They are the largest shareholder. Sam Ifergan, founder of iGan Partners, co-founded Exact Imaging. This deep relationship ensures continuous support. iGan has assisted with company formation. They also facilitated intellectual property licensing. Their support spans clinical development and initial commercialization. All financing rounds to date have seen their backing. This partnership provides critical sector expertise and operational guidance. It helps scale innovations that improve patient outcomes.
The impact of ExactVu™ on prostate cancer care is profound. It offers a more precise, accessible alternative for diagnosis. Early detection remains key to successful treatment. The system’s high resolution aids in targeting suspicious lesions. This minimizes unnecessary biopsies. It also reduces patient discomfort. Exact Imaging’s technology addresses a critical need in men’s health. It provides urologists with a powerful diagnostic solution.
Exact Imaging is set for continued strong growth. The company’s innovative technology, combined with robust clinical evidence, sets it apart. Its expanding global commercial footprint promises broad market penetration. This financing round reinforces its leadership in micro-ultrasound imaging. Exact Imaging is transforming prostate cancer diagnosis. It is improving patient outcomes worldwide. The future of urologic imaging looks sharper, thanks to ExactVu™.